Data published in PLOS ONE show Mymetics’ HIV-1 Innovative vaccine is safe and elicits strong immunogenicity

Epalinges, Switzerland, 21 February 2013

Results from a randomized study published in PLOS ONE1 today demonstrate that Mymetic’ innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine is safe and well tolerated and demonstrates a high level of immunogenicity in a Phase I trial involving 24 healthy women. The publication highlights that vaccine-induced mucosal antibodies may contribute to reduce sexually transmitted HIV-1. Mymetics Corporation is a pioneer in the
development of vaccines that use the human mucosal system, the body’s first line of defense, to prevent transmission of infectious diseases.

Media Name Media Type Description Download
130220 Mymetics Corporation - Press release 20 02 2013 - PLOSONE PDF Download